Impact of HPV vaccination: Achievements and future challenges
J.M. Brotherton.
Papillomavirus Research (2019)
The remarkable impact of bivalent HPV vaccine in Scotland
Brotherton Julia M L..
BMJ 2019; 365 :l1375
Evaluation of self-collected vaginal specimens for the detection of high-risk HPV infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.
Toliman P,
Kaldor J,
Badman SG,
Phillips S,
Tan G,
Brotherton JM,
Saville M,
Vallely A,
Tabrizi S.
(2018) Clinical Microbiology and Infection. doi: 10.1016/j.cmi.2018.05.025.
Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.
Velentzis L S.,
Smith M A.,
Simms KT.,
Lew JB,
Hall M,
Hughes S,
Yuill S,
Killen J,
Keane A,
Butler K,
Darlington-Brown J,
Hui H,
Brotherton JML.,
Skinner R,
Brand A,
Roeske L,
Heley S,
Carter J,
Bateson D,
Frazer I,
Garland SM.,
Guy R,
Hammond I,
Grogan P,
Arbyn M,
Castle PE.,
Saville M,
Armstrong BK.,
Canfell K.
(2019) Gynecologic Oncology 152(3): 465-471. doi: 10.1016/j.ygyno.2018.12.019
Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
Farhana Sultana,
Karen Winch,
Marion Saville,
Julia M.L. Brotherton.
International Journal of Cancer 2019.
Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact.
Julia ML. Brotherton,
David Hawkes,
Farhana Sultana,
Michael J. Malloy,
Dorothy A. Machalek,
Megan A. Smith,
Suzanne M. Garland,
Marion Saville.
Vaccine 2018.
The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall M. T.,
Simms K. T.,
Lew J. B.,
Smith M. A.,
Brotherton J. M.,
Saville M.,
Frazer I. H.,
Canfell K..
(2019) Lancet Public Health 4(1): e19-e27. 10.1016/s2468-2667(18)30183-x
Clinical validation of the cobas HPV test on the cobas 6800 system for the purpose of cervical screening.
Marion Saville,
Farhana Sultana,
Michael J. Malloy,
Louiza S. Velentzis,
Michael Caruana,
Ellen L. O. Ip,
Marco H. T. Keung,
Karen Canfell,
Julia M. L. Brotherton,
David Hawkes.
J Clin Microbiol. 2018 Nov 21. pii: JCM.01239-18.
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C.,
Brotherton J. M.,
Pillsbury A.,
Jayasinghe S.,
Donovan B.,
Macartney K.,
Marshall H..
(2018) Euro Surveill 23(41). doi:10.2807/1560-7917.es.2018.23.41.1700737
Should Cervical Cancer Screening be Performed Before the Age of 25 Years?
Moscicki A. B.,
Perkins R. B.,
Saville M.,
Brotherton J. M. L..
(2018) J Low Genit Tract Dis 22(4): 348-351. doi: 10.1097/LGT.0000000000000434.
HPV testing as part of the renewed National Cervical Screening Program
Hawkes D..
Australian Journal of General Practice. AJGP Vol. 47, No. 7, July 2018
There are no old roads to new directions.
Roeske L. .
Australian Journal of General Practice. AJGP Vol. 47, No. 7, July 2018
Human papillomavirus vaccination update: nonavalent vaccine and the two-dose schedule. Australian Journal of General Practice
Brotherton JML .
AJGP Vol. 47, No. 7, July 2018
Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study
Skye McGregor,
Dina Saulo,
Julia Brotherton,
Bette Liu,
Samuel Phillips,
S. Rachel Skinner,
Michele Luey,
Lisa Oliver,
Mary Stewart,
Sepehr N. Tabrizi,
Suzanne Garland,
John M. Kaldor.
Vaccine 36 (2018) 4311–4316
“Lest we forget” as we move forward with cervical screening
Marion Saville,
Orla McNally.
Aust N Z J Obstet Gynaecol 2018; 58: 265–266
Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program
Suzanne M. Garland,
Alyssa M. Cornall,
Julia M.L. Brotherton,
John D. Wark,
Michael J. Malloy,
Sepehr N. Tabrizi,
on behalf of the VACCINE study group.
Vaccine 36 (2018) 3221–3230
Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland
Paramita Dasgupta,
Lisa J. Whop,
Abbey Diaz,
Susanna M. Cramb,
Suzanne P. Moore,
Julia M.L. Brotherton,
Joan Cunningham,
Patricia C. Valery,
Dorota Gertig,
Gail Garvey,
John R. Condon,
Dianne L. O’Connell,
Karen Canfell,
Peter D. Baad.
Geographical Research 2018
Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012)
Abbey Diaz,
Peter D. Baade,
Patricia C. Valery,
Lisa J. Whop,
Suzanne P. Moore,
Joan Cunningham,
Gail Garvey,
Julia M. L. Brotherton,
Dianne L. O'Connell,
Karen Canfell,
Diana Sarfati,
David Roder,
Elizabeth Buckley,
John R. Condon.
PLOS One 13(5): e0196764. May 8, 2018
Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination
Dorothy A. Machalek,
Suzanne M. Garland,
Julia M. L. Brotherton,
Deborah Bateson,
Kathleen McNamee,
Mary Stewart,
S. Rachel Skinner,
Bette Liu,
Alyssa M. Cornall,
John M. Kaldor,
Sepehr N. Tabrizi.
The Journal of Infectious Diseases Volume 217, Issue 10, 23 April 2018, Pages 1590–1600
Reply to San Giorgi and Dikkers
Daniel Novakovic,
Julia M. L. Brotherton.
The Journal of Infectious Diseases. Vol 217, Issue 9, 11 April 2018
Safety of Human Papillomavirus Vaccines: An Updated Review
Phillips Anastasia,
Patel Cyra,
Pillsbury Alexis,
Brotherton Julia,
Macartney Kristine.
Drug Safety April 2018, Volume 41, Issue 4, pp 329–346
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25 to 69 years living in Australia
Karen Canfell,
Marion Saville,
Michael Caruana,
Val Gebski,
Jessica Darlington-Brown,
Julia ML Brotherton,
Stella Heley,
Philip E. Castle.
BMJ Open 2018 8: doi: 10.1136/bmjopen-2017-016700
IPVS Statement Moving towards Elimination of Cervical Cancer as a Public Health Problem
SM Garland,
A Giuliano,
JML Brotherton,
AB Moscicki,
M Stanley,
AM Kaufmann,
N Bhatla,
R Sankaranarayanan,
JM Palefsky,
S de Sanjose,
on behalf of IPVS.
Papillomavirus Research Available online 27 Feb 2018
Self-collection for under-screened women as part of the renewed National Cervical Screening Program: A Pilot Study
Saville M,
Hawkes D,
Mclachlan E,
Anderson S,
Arabena K. .
Current Oncology, Curr Oncol. 2018 Feb;25(1):e17-e26
Completing the cervical screening pathway: An Australian pilot of HPV self-collection for under-screened and never-screened women
McLachlan E,
Anderson S,
Saville M,
Hawkes D,
Arabena K..
Current Oncology, Curr Oncol. 2018 Feb;25(1):e27-e32
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT,
Simms Kate,
Lew Jie-Bin,
Smith Megan,
Saville A Marion,
Canfell Karen.
(2018) PLOS One 13(2).
Population based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage
Julia M.L. Brotherton,
Paul N. Bloem.
Best Practice & Research Clinical Obstetrics and Gynaecology 47 (2018) 42e58
A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program
Daniel Novakovic,
Alan T L Cheng,
Yvonne Zurynski,
Robert Booy,
Paul J Walker,
Robert Berkowitz,
Henley Harrison,
Robert Black,
Christopher Perry,
Shyan Vijayasekaran,
David Wabnitz,
Hannah Burns,
Sepehr N Tabrizi,
Suzanne M Garland,
Elizabeth Elliott,
Julia M L Brotherton.
J Infect Dis. 2018 Jan 4;217(2):208-212.
Sisters doing it for themselves A safe and acceptable self-collection model for cervical cancer screening
Sandy Anderson – Ballarat and District Aboriginal Co-operative (BADAC),
Associate Professor Marion Saville – Victorian Cytology Service Ltd (VCS),
Dr David Hawkes – Victorian Cytology Service Ltd (VCS),
Professor Kerry Arabena – The Centre for Health Equity and the Indigenous Health Equity,
Elizabeth McLachlan – The University of Melbourne,
Ruvimbo Bako – Department of Health and Human Services,
Rachael Andersen – Department of Health and Human Services.
Poster - 6th Annual NHMRC Symposium on Research Translation co-hosted with the Lowitja Institute
A new era for cervical screening in Australia: Watch this space
Hammond I.,
Canfell K.,
Saville M..
Aust N Z J Obstet Gynaecol, 57: 499–501. doi:10.1111/ajo.12669
Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination Results of the Compass pilot randomised trial
Karen Canfell,
Michael Caruana,
Val Gebski,
Jessica Darlington-Brown,
Stella Heley,
Julia Brotherton,
Dorota Gertig,
Chloe J. Jennett,
Annabelle Farnsworth,
Jeffrey Tan,
C. David Wrede,
Philip E. Castle,
Marion Saville.
PLOS Medicine 19 September, 2017
Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination
Brotherton JML,
Tabrizi SN,
Phillips S,
Pyman J,
Cornall AM,
Lambie N,
Anderson L,
Cummings M,
Payton D,
Scurry JP,
Newman M,
Sharma R,
Saville M,
Garland SM.
Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
Alexis J. Pillsbury,
Helen E. Quinn,
TaNisha D. Evans,
Peter B. McIntyre,
Julia M. L. Brotherton..
Clin Infect Dis 2017, 3rd July 2017
Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Jie-Bin Lew,
D James B St John,
Xiang-Ming Xu,
Marjolein J E Greuter,
Michael Caruana,
Dayna R Cenin,
Emily He,
Marion Saville,
Paul Grogan,
Veerle M H Coupé,
Karen Canfell.
Lancet Public Health 2017; 2: e331–40, Published Online, June 26, 2017
Addressing Confusion about the Risks and Benefits of Co-Testing versus Human Papillomavirus Tests for Cervical Cancer
Grace Tan,
David Hawkes.
Acta Cytologica May 5, 2017 DOI:10.1159/000472244
Cost-effectiveness estimates: the need for complete reporting
Jie-Bin Lew,
Kate T Simms,
Megan A Smith,
Marion Saville,
Ian Hammond,
Karen Canfell.
The Lancet Vol 2 May 2017
HPV vaccine coverage is increasing in Australia
Julia ML Brotherton,
Karen L Winch,
Lisette Bicknell,
Genevieve Chappell,
Marion Saville.
Medical Journal of Australia MJA 206 (6) 3 April 2017 doi: 10.5694/mja16.00958
Annual Immunisation Coverage Report 2014
Hull BP,
Hendry AJ,
Dey A,
Beard FH,
Brotherton JM,
McIntyre PB.
BP Hull et al. Commun Dis Intell Q Rep 41 (1), E68-E90. 2017 Mar 31.
Response to “Vaccine-related serious adverse events might have been under-recognised in the pivotal HPV vaccine randomized trial”
David Hawkes.
Clin Rheumatol. 2017 Mar 25. DOI: http://dx.doi.org/10.1007/s10067-017-3609-6
Response to: HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women withpre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study
D. Hawkes,
W. Wilkinson & R. A. Dunlop.
Journal of Internal Medicine 2017 doi:10.1111/joim.12602
Self collection Pilot Project improving access to cervical screening for underscreened women
Developed by the University of Melbourne and Victorian Cytology Service Ltd for the Victorian Department of Health and Human Services.
Evaluation Report February 2017
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated
Lew JB,
Simms KT,
Smith MA,
Hall M,
Kang YJ,
Xu XM,
Caruana M,
Velentzis LS,
Bessell T,
Saville M,
Hammond I,
Canfell K..
Lancet Public Health. 2017 Feb;2(2):e96-e107. Epub 2017 Feb 7.
Time to clinical investigation after a high-grade abnormal Pap test for indigenous and non-indigenous women in Queensland, 2000–2011.
Whop LJ,
Baade P,
Brotherton JML,
Canfell K,
Cunningham J,
Gertig DM,
Lokuge K ,
Garvey G ,
Moore SP,
Diaz A,
O’Connell DL,
Valery PC,
Roder D,
Condon JR..
Med J Aust 2017; 206 (2): 73-77. doi:10.5694/mja16.00255
Optimal Management Strategies for Primary HPV Testing for Cervical Screening – Cost-
Simms KT,
Hall M,
Smith MA,
Lew JB,
Hughes S,
Yuill S,
Hammond I,
Saville M,
Canfell K.
PLoS One. 2017 Jan 17;12(1):e0163509.
Progress in HPV vaccination in low-and lower-middle- income countries
D. Scott LaMontagne,
Paul J.N. Bloem,
Julia M.L. Brotherton,
Katherine E. Gallagher,
Ousseynou Badiane,
Cathy Ndiaye.
Int J Gynecol Obstet 2017; 138 (Suppl. 1): 7–14
IPVS Policy statement on safety of HPV vaccines
Garland SM,
Stanley M,
Brotherton J,
Mosckiki A-G,
Bhatla N,
Kaufmann AM,
Sankaranarayanan R,
Palefsky J.
Papillomavirus Research 2016; 2: 9-10
Monitoring the impact of HPV vaccine in males – considerations and challenges
Brotherton JML,
Giuliano A,
Markowitz L,
Dunne E,
Ogilvie G.
Papillomavirus Research 2016; 2: 106-111
The population impact of HPV vaccination programmes on HPV infection with the non-vaccine HPV genotypes: a systematic review and meta-analysis.
Soldan K,
Lehtinen M,
Beddows S,
Brisson M,
Brotherton JM,
Chow EP,
Cummings T,
Drolet M,
Fairley CK,
Garland SM,
Kahn JA,
Kavanagh K,
Markowitz L,
Pollock KG,
Söderlund-Strand A,
Sonnenberg P,
Tabrizi SN,
Tanton C,
Unger E,
Thomas SL. .
Emerging Infectious Diseases.2016;22(10):1732-1740.
Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch up
Staples C,
Butler M,
Nguyen J,
Durrheim DN,
Cashman P,
Brotherton JML.
Sexual Health 2016. Published online 29 August 2016
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines
Julia M.L. Brotherton,
Mark Jit,
Patti E. Gravitt,
Marc Brisson,
Aim ee R. Kreimer,
Sara I. Pai,
Carole Fakhry,
Joseph Monsoneg ,
Silvia Franceschi.
Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22
Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia
Farhana Sultana,
Dallas R. English,
Julie A. Simpson,
Kelly T. Drennan,
Robyn Mullins,
Julia M.L. Brotherton,
C. David Wrede,
Stella Heley,
Marion Saville,
Dorota M. Gertig.
International Journal of Cancer Volume 139, Issue 2, pages 281–290, 15 July 2016
Primary Prevention of HPV through Vaccination: Update on Current Global Status
Brotherton JML,
Zuber PLF,
Bloem PJN.
Curr Obst Gynecol Reports 2016. Published online 7 July 2016.
The Role of Pejorative Search Terms and Professional Antivaccine Advocates on Search Engine Results for Human Papillomavirus Vaccine
Tracey McDermott,
David Hawkes Ph.D.,
Joanne Benhamu,
R.N..
Journal of Adolescent Health 58 (2016) 691e694
Changes to the cervical cancer screening program in Australia
Karen Canfell,
Marion Saville,
Ian Hammond,
Lara Roeske.
Medicine Today, May 2016, 17(5), 59-82
The First Comprehensive Report on Indigenous Australian Women’s Inequalities in Cervical Screening: A Retrospective Registry Cohort Study in Queensland, Australia (2000-2011)
Lisa J. Whop,
Gail Garvey,
Peter Baade,
Joan Cunningham,
Kamalini Lokuge,
Julia M. L. Brotherton,
Patricia C. Valery,
Dianne L. O'Connell,
Karen Canfell,
Abbey Diaz,
David Roder,
Dorota Gertig,
Suzanne P. Moore,
John R. Condon.
Cancer: Volume 122, Issue 10, pages 1560–1569, May 15, 2016
Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use
Megan A. Smith,
Dorota Gertig,
Michaela Hall,
Kate Simms,
Jie-Bin Lew,
Michael Malloy,
Marion Saville,
Karen Canfell..
BMC Health Services Research (2016) 16:147
Juvenile recurrent respiratory papillomatosis: 10 year audit and Australian prevalance estimates
Novakovic D,
Cheng A,
Baguley K,
Walker P,
Harrison H,
Soma M,
Malloy M,
Brotherton JML.
The Laryngoscope 2016. 2016 Apr 14.
Cervical Abnormalities Are More Common among Indigenous than Othe Australian Women: A Retrospective Record-Linkage Study, 2000-2011
Lisa J. Whop,
Peter Baade,
Gail Garvey,
Joan Cunningham,
Julia M. L. Brotherton,
Kamalini Lokuge,
Patricia C. Valery,
Dianne L. O’Connell,
Karen Canfell,
Abbey Diaz,
David Roder,
Dorota M. Gertig,
Suzanne P. Moore,
John R. Condon.
PLOS ONE, April 11, 2016
Immunisation coverage annual report, 2013
Hull BP,
Dey A,
Beard FH,
Menzies RI,
Brotherton JM,
McIntyre PD.
Commun Dis Intell Q Rep. 2016 March 31;40(1): E146-69
HPV vaccine impact in Australian women: ready for an HPV-based screening program
Julia ML Brotherton,
Dorota M Gertig,
Cathryn May,
Genevieve Chappell,
Marion Saville.
MJA 204 (5) 21 March 2016
Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project.
Whop LJ,
Diaz A,
Baade P,
Garvey G,
Cunningham J,
Brotherton JML,
Canfell K,
Valery PC,
O'Connell D,
Taylor C,
Moore SP,
Condon JR..
BMJ Open 2016;6:e009540
Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence
David Hawkes,
Jim Buttery.
Curr Opin Obstet Gynecol: 2016
HPV Vaccination: Current Global Status
Julia M.L Brotherton,
Paul J.N Bloem.
Current Obstetrics and Gynecology Reports 2015
HPV vaccines: so much learnt, so many more lessons to come
Julia M.L Brotherton.
The Lancet Oncology
Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia
Julia M.L. Brotherton,
Michael Malloy,
Alison C. Budd,
Marion Saville,
Kelly T. Drennan,
Dorota M. Gertig.
Papillomavirus Research Volume 1, December 2015, Pages 59–73
Cervical cancer prevention in Australia: Planning for the future
A. Marion Saville.
Cancer Cytopathology, Vol 124, 4, 235-240
Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-participation
Brotherton JML,
Piers LS,
Vaughan L.
Sexual Health 2015
Women’s experience with home-based self- sampling for human papillomavirus testing
Farhana Sultana,
Robyn Mullins,
Dallas R. English,
Julie A. Simpson,
Kelly T. Drennan,
Stella Heley,
C. David Wrede,
Julia M. L. Brotherton,
Marion Saville,
Dorota M. Gertig.
BMC Cancer (2015) 15:849
The acceptability and cost of a home-based chlamydia retesting strategy: findings from the REACT randomised controlled trial
Smith K.,
Kaldor J.,
Hocking J.,
Jamil M.,
McNulty A.,
Read P.,
Bradshaw C.,
Chen M.,
Fairley C.,
Wand H.,
Worthington K.,
Blake S.,
Knight V.,
Rawlinson W.,
Saville M.,
Tabrizi S.,
Garland S.,
Donovan B.,
Guy R..
BMC Public Health.2016, 16:83 DOI: 10.1186/s12889-016-2727-4
Human Papillomavirus (HPV) Vaccination Safety Assessment: The Methods Matter
Julia M. L. Brotherton,
Kristine K Macartney,
Etsuko Miyagi,
Jim P. Buttery.
Intern Med 54: 2531, 2015
HPV.edu study protocol: a cluster randomized controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents
S. Rachel Skinner,
Cristyn Davies,
Spring Cooper,
Tanya Stoney,
Helen Marshall,
Jane Jones,
Joanne Collins,
Heidi Hutton,
Adriana Parrella,
Gregory Zimet,
David G. Regan,
Patti Whyte,
Julia M. L. Brotherton,
Peter Richmond,
Kirsten McCaffrey,
Suzanne M. Garland,
Julie Leask,
Melissa Kang,
Annette Braunack-Mayer,
John Kaldor,
Kevin McGeechan.
BMC Public Health 2015
Current status of human papillomavirus vaccination
JML Brotherton,
GS Ogilvie.
Curr Opin Oncol 2015:27(5):399-404
HPV prophylactic vaccines: lessons learned from 10 years experience
Brotherton JML.
Future Virology, Vol. 10, No. 8 , Pages 999-1009
A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing.
Farhana Sultana,
Dorota M. Gertig,
C. David Wrede,
Dallas R. English,
Julie A. Simpson,
Kelly T. Drennan,
Julia M.L. Brotherton,
Gillian Phillips,
Stella Heley,
Philip E. Castle,
Marion Saville.
Journal of Clinical Virology 2015 69 (2015) 210–213
Measuring HPV vaccination coverage in Australia:comparing two alternative population-based denominators
Bianca Barbaro,
Julia M.L. Brotherton.
Australian and New Zealand Journal of Public Health Aust NZ J Public Health. 2015; Online; 2015
Could one dose of bivalent HPV vaccine prevent cervical cancer?
Julia ML Brotherton.
Lancet Oncol 2015:16(7):739-40
Human papillomavirus prevalence to age 60 years among Australian women prevaccination
Julia M. L. Brotherton,
John R. Condon,
Peter B. McIntyre,
Sepehr N. Tabrizi,
Michael Malloy,
Suzanne M. Garland,
and on behalf of the WHINURS study group .
Sexual Health, June 2015
Human Papillomavirus control. How are we going with vaccination coverage seven years in
Brotherton JML,
Chappell G,
Brosi J,
Bicknell L,
Winch K,
Barbaro B,
Saville M.
Poster presentation Communicable Disease Control Conference - June 2015
Women’s views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting.
Sultana F,
Mullins R,
Murphy M,
English DR,
Simpson JA,
Drennan KT,
Heley S,
Wrede CD,
Brotherton JM,
Saville M,
Gertig DM.
Sexual Health 2015: 12(4): 279-286
Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer—Could a Schistosomiasis Vaccine be the Third?
Michael H. Hsieh,
Julia M. L. Brotherton,
Afzal A. Siddiqui.
PLOS Neglected Tropical Diseases, May 2015
The effect of making a ‘third dose assumption’ on HPV coverage estimates
Brotherton JML,
Winch K..
Australian and New Zealand Journal of Public Health: Volume 39, Issue 2, pages 193–194, April 2015
Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia
Julia M. L. Brotherton,
A. Marion Saville,
Cathryn L. May,
Genevieve Chappell,
Dorota M. Gertig.
Cancer Causes and Control: Published On-Line 25th March 2015
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Mélanie Drolet PhD,
Élodie Bénard BSc,
Marie-Claude Boily PhD,
Hammad Ali PhD,
Louise Baandrup MD,
Heidi Bauer MD,
Simon Beddows PhD,
Jacques Brisson DSc,
Julia M L Brotherton BMed,
Teresa Cummings BA,
Basil Donovan MD,
Christopher K Fairley PhD,
Elaine W Flagg PhD,
Anne M Johnson MD,
Jessica A Kahn MD,
Kimberley Kavanagh PhD,
Susanne K Kjaer MD,
Erich V Kliewer PhD,
Philippe Lemieux-Mellouki MSc,
Lauri Markowitz MD,
Aminata Mboup MSc,
David Mesher MSc,
Linda Niccolai PhD,
Jeannie Oliphant FAChSHM,
Kevin G Pollock PhD,
Kate Soldan PhD,
Pam Sonnenberg PhD,
Sepehr N Tabrizi PhD,
Clare Tanton PhD,
Dr Marc Brisson PhD.
Lancet Infect Dis 2015: Published Online March 3, 2015
Asking About Human Papillomavirus Vaccination and the usefulness of Registry Validation: A Study of Young Women Recruited Using Facebook
Bharathy Gunasekaran,
Yasmin Jayasinghe,
Julia M.L. Brotherton,
Yeshe Fenner,
Elya E. Moore,
John D. Wark,
Ashley Fletcher,
Sepehr N. Tabrizi,
Suzanne M. Garland.
Vaccine, 33, no. 6., pp. 749-832, 4 Feb 2015.
Two or three doses of human papillomavirus vaccine?
Brotherton JML.
BMJ 2015;350:g7778 (Published 07 January 2015)
Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia
Julia ML Brotherton,
Michael R Batchelor,
Michelle O Bradley,
Scott A Brown,
Simone M Duncombe,
Dennis Meijer,
Lauren E Tracey,
Maureen Watson,
Rosalind J Webby.
Communicable Disease Intelligence 2015 Vol 39, No2
HPV Vaccination: Current Global Status
Brotherton JML,
Bloem PJN.
Curr Obstet Gynecol Rep 2015
Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program
Sarah L. Osborne,
Sepehr N. Tabrizi,
Julia M.L. Brotherton,
Alyssa M. Cornall,
John D. Wark,
C. David Wrede,
Yasmin Jayasinghe,
Dorota M. Gertig,
Marian K. Pitts,
Suzanne M. Garland,
on behalf of the VACCINE Study group..
Vaccine, 33, 2015, pp. 201-208.
What you need to know about: Human Papillomavirus Vaccination
Brotherton JML.
British Journal of Hospital Medicine 2014; 75(11): C165-C168
Human Papillomavirus Vaccination
Julia ML Brotherton.
British Journal of Hospital Medicine, November 2014, 75, no.11.
Immunisation Coverage, 2012
Brynley P Hull,
Aditi Dey,
Rob I Menzies,
Julia M Brotherton,
Peter B McIntyre.
Communicable Diseases Intelligence, 38, no. 3, September 2014, pp. E208-31.
Cervical screening rates for women vaccinated against human papillomavirus
Alison C Budd,
Julia M L Brotherton,
Dorota M Gertig,
Theresa Chau,
Kelly T Drennan,
Marion Saville.
Med J Aust 2014; 201 (5): 279-282
High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: A cohort study with 10 years of follow-up.
Sultana F,
English D,
Simpson J,
Canfell K,
Gertig D,
Saville M.
International Journal of Cancer, 2014, 135 (5), 1 Sept 2014, 1213-19
Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: What do you need to know? [Letter]
Julia ML Brotherton,
C David H Wrede.
ANZJOG, 2014, 54 (4): 393-396. Article first published online: 13 AUG 2014.
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Sepehr N Tabrizi,
Julia M L Brotherton,
John M Kaldor,
S Rachel Skinner,
Bette Liu,
Deborah Bateson,
Kathleen McNamee,
Maria Garefalakis,
Samuel Phillips,
Eleanor Cummins,
Michael Malloy,
Suzanne M Garland.
Lancet Infect Dis, 2014, published online August 6, 2014.
HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program
Sepehr N. Tabrizi,
Julia M.L. Brotherton,
Matthew P. Stevens,
John R. Condon,
Peter McIntyre,
David Smith,
Suzanne M. Garland,
on behalf of the WHINURS group.
Journal of Clinical Virology, 2014, 60 (3), July 2014, 250-56.
Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?
Bianca Barbaro,
Julia M.L. Brotherton..
Australian and New Zealand Journal of Public Health, 2014, 38 (4), published online 24 June 2014.
Human papillomavirus vaccination: Where are we now?
Julia Brotherton.
Journal of Paediatrics and Child Health, 2014, 50 (8), published online 9 June 2014.
How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions
Callegari ET,
Tabrizi SN,
Pyman J,
Saville M,
Cornall AM,
Brotherton JML,
Garland SM..
Vaccine, 2014, 32, 4082-4088. Published online 22 May 2014
Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive tests
Kirsty S Smith,
Jane S Hocking,
Marcus Chen,
Christopher K Fairley,
Anna McNulty,
Phillip Read,
Catriona S Bradshaw,
Sepehr N Tabrizi,
Handan Wand,
Marion Saville,
William Rawlinson,
Suzanne M Garland,
Basil Donovan,
John M Kaldor,
Rebecca Guy.
BMC Infectious Diseases, 2014,14:223.
Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never-and under-screened women in Australia
Sultana F,
English DR,
Simpson JA,
Brotherton JML,
Drennan K,
Mullins R,
Heley S,
Wrede CD,
Saville M,
Gertig DM.
BMC Cancer, 2014. 14:207. DOI:10.1186/1471-2407-14-207
Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: a case-control study nested within a population-based screening program in Australia
Crowe E,
Pandeya N,
Brotherton JML,
Dobson AJ,
Kisely S,
Lambert SB,
Whiteman DC.
BMJ, 2014, 348:g1458, doi: 10.1136/bmj.g.1458. Published on-line 4 Mar 2014.
Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011.
Liu B,
Donovan B,
Brotherton JML,
Saville M,
Kaldor JM..
Sex Transm Infect, 2014, 25 February. doi:10.1136/sextrans-2013-051307
Barriers to better three-dose coverage with HPV vaccination in school-based programs.
Watson M,
D'Onise K,
Lynch J,
Brotherton JML.
Aust N Z J Public Health, 2014, 38(1):91-92.
Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey.
Brotherton JML,
Liu B,
Donovan B,
Kaldor JM,
Saville M.
Vaccine, 2014, 32 (5): 592-597, 23 Jan 2014.
Immunisation coverage annual report, 2011
Hull BP,
Dey A,
Menzies RI,
Brotherton JML,
McIntyre PB.
Commun Dis Intell Q Rep. 2013 Dec 31;37(4):E291-312
Human papillomavirus vaccine national catch up program: insights into under notification
Laemmele-Ruff I,
Barbaro B,
Brotherton JML.
Aust Fam Physician, 2013, 42(12): 880-884.
Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.
Brotherton JML,
Murray SL,
Hall MA,
Andrewartha LK,
Banks CA,
Meijer D,
Pitcher HC,
Scully MM,
Molchanoff L..
Med J Aust, 2013, 199 (9) :614-617, doi: 10.5694/mja13.10272
Safety of the quadrivalent human papillomavirus vaccine [editorial].
Brotherton JML..
BMJ, 2013, 347:f5631
Utility of reports and routine correspondence from the National HPV Vaccination Program Register.
Brotherton JML,
Batchelor M,
Winch K..
Med J Aust, 2013, 199 (7): 463.
HPV testing in the National Cervical Screening Program, When is it recommended?
Heley S..
Australian Family Physician Vol. 42, No. 7, July 2013: 463:466.
The Impact of Vaccination and what it means for Cytology Screening
Gertig D,
Brotherton J,
Saville M.
HPV Today, 2013, July.
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
Young EJ,
Tabrizi SN,
Brotherton JM,
Wark JD,
Pyman J,
Saville M,
Wrede CD,
Jayasinghe Y,
Tan J,
Gertig DM,
Pitts M,
Garland SM.
BMC Cancer 2013 June 19;13:296.
Safety of human papillomavirus vaccines: a review
Macartney KK,
Chiu C,
Georgousakis M,
Brotherton JM.
Drug Safety 2013 Jun;36(6):393-412.
Adapting the Australian system: is an organized screening program feasible in Malaysia? – an overview of cervical cancer screening in both countries
Rashid RM,
Dahlui M,
Mohamed M,
Gertig D.
Asian Pac J Cancer Prev 2013;14(3):2141-6.
Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study.
Gertig DM,
Brotherton JML,
Budd AC,
Drennan K,
Chappell G,
Saville AM.
BMC Medicine, 2013, 11:227, doi:10.1186/1741-7015-11-227
Why a special issue on anal cancer and what is in it?
Fairley CK,
Brotherton JM,
Hillman R,
Grulich AE..
Sexual Health 2012 Dec;9(6):501-3.
Time for a strategic research response to anal cancer
Grulich AE,
Hillman R,
Brotherton JM,
Fairley CK.
Sexual Health 2012 Dec;9(6):628-31.
Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM,
Mullins RM..
Cancer Epidemiol, 2012, Jun; 36(3): 298-302. Epub 2011 Dec 8.
Expenditure and resource utilisation for cervical screening in Australia
Lew JB,
Howard K,
Gertig D,
Smith M,
Clements M,
Nickson C,
Shi JF,
Dyer S,
Lord S,
Creighton P,
Kang YJ,
Tan J,
Canfell K.
BMC Health Serv Res 2012 Dec 5;12:446.
Fall in human papillomavirus prevalence following a national vaccination program
Tabrizi SN,
Brotherton JM,
Kaldor JM,
Skinner SR,
Cummins E,
Liu B,
Bateson D,
McNamee K,
Garefalakis M,
Garland SM.
J Infect Dis 2012 Dec 1;206(11): 1645-51.
Human papillomavirus vaccine introduction – the first five years
Markowitz LE,
Tsu V,
Deeks SL,
Cubie H,
Wang SA,
Vicari AS,
Brotherton JM.
Vaccine 2012 Nov 20:30 Suppl 5:F139-48.
Fall in human papillomavirus prevalance following a national vaccination program
Tabrizi SN,
Brotherton JML,
Kaldor JM Skinner SR,
Cummins E,
Liu B,
Bateson D,
McNamee K,
Garefalakis M,
Garland SM.
Journal of Infectious Diseases. 2012;206(11):1645-51
Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study
Georgousakis M,
Jayasinghe S,
Brotherton J,
Gilroy N,
Chiu C,
Macartney K..
Lancet Infect Dis., 2012, 12 (8), Aug 2012, 627-34.
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease
Arbyn M,
de Sanjose S,
Saraiya M,
Sideri M,
Palefsky J,
Lacey C,
Gillison M,
Bruni L,
Ronco G,
Wentzensen N,
Brotherton J,
Qiao YL,
Denny L,
Bornstein J,
Abramowitz L,
Giuliano A,
Tommasino M,
Monsonego J.
Int J Cancer 2012 Nov 1;131(9):1969-82. EPub 2 July 2012.
Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria
Barbaro B,
Brotherton JML,
Gertig D..
Med J Aust, 2012, Apr 16; 196 (7): 445.
Human papillomavirus and head and neck cancers: emerging trends and improving survival [letter to the editor].
Brotherton JML,
Stein A,
Conway L,
Grulich A,
Law M,
Hocking J..
Aust NZ J Pub Health, 2012, Apr; 36(2): 195-6.
Genital HPV types in Australia [letter].
Brotherton JML,
Garland S,
Donovan B.
Lancet Infect Dis., 2012, Feb;12(2):102-3.
Does human papillomavirus type 16 or 18 prevalence in CIN3 lesions vary by age? An important issue for post vaccination surveillance.
Brotherton JML,
Tabrizi SN,
Garland SM..
Future Micobiol., 2012, Feb; 7(2), 193-9.
Mobile phones are a viable option for surveying young Australian women: a comparison of two telephone survey methods.
Liu B,
Brotherton JML,
Shellard D,
Donovan B,
Saville M,
Kaldor JM..
BMC Medical Research Methodology, 2011, 11: 159, doi:10.1186/1471-2288-11-159
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA,
Lew JB,
Walker RJ,
Brotherton JML,
Nickson C,
Canfell K..
Vaccine, 2011, 29 (48), 8 Nov 2011, 9112-22
Adolescent and young adult HPV vaccination in Australia: achievements and challenges.
Garland SM,
Skinner SR,
Brotherton JML.
Prev Med, 2011, Oct 1; 53 Suppl 1: S29-35.
Primary prophylactic HPV vaccination programs: future perspective on global impact.
Brotherton JML,
Gertig DM.
Expert Rev Anti Infect Ther, Aug 2011, 9 (8): 627-39.
Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study
Brotherton JML,
Fridman M,
May CL,
Chappell G,
Saville AM,
Gertig DM.
The Lancet 2011; 377:2085-2092
Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study
Brotherton JML,
Fridman M,
May C,
Chappell G,
Saville AM,
Gertig DM.
The Lancet, 2011, 377(9783), 11 Jun 2011, 2085-92.
Catching up with the catch- up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J,
Gertig D,
Chappell G,
Rowlands L,
Saville M..
Commun Dis Intell, Jun 2011, 35(2): 197-201.
Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia
Gertig DM,
Brotherton JML,
Saville M.
Sexual Health, 2011, 8: 171-178.
Human papillomavirus prevalence amongst Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program.
Garland SM*,
Brotherton JML*,
Condon JR,
McIntyre PB,
Stevens MP,
Smith DW,
Tabrizi SN,
[* joint first authors].
BMC Med., 2011, 9(1): 104.
Trends in anal cancer in Australia, 1982-2005
Jin F ,
Stein AN,
Conway EL,
Regan D,
Law M,
Brotherton JML,
Hocking J ,
Grulich A..
Vaccine, 2011, 29 (12), 9 Mar 2011, 2322-27.
Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers
Hocking J,
Stein A,
Conway L,
Grulich A,
Law M,
Brotherton JML..
British Journal of Cancer, 2011, 104, 886-891. Published online 1 Feb 2011.
Approaches to Monitoring Biological Outcomes for HPV Vaccination: Challenges of Early Adopter Countries
Wong CA,
Saraiya M,
Hariri S,
Eckert L,
Howlett RI,
Markowitz LE,
Brotherton JML.
Vaccine, 2011, 29 (5): 878-885.
“I just signed”: Factors influencing decision making for school-based HPV vaccination.
Cooper Robbins SC,
Bernard D,
McCaffery K,
Brotherton JML,
Skinner SR..
Health Psychology, 2010, 29 (6): 618-25.
Australian HPV Surveillance [letter]
Brotherton JML,
Kaldor JM,
McIntyre PB..
Vaccine, 2010, 28 (47), 7453-7454.
Human papillomavirus genotype detection from archival papanicolaou-stained cervical tests.
Tabrizi S,
Taylor N,
McCullough MJ,
Phillips G,
Wark J,
Gertig D,
Petersen R,
Saville M,
Garland S..
Cancer Cytopathology, 2010, 118(6). Published online 12 Oct 2010.
Sexual Health
.
Special Issue: Human Papillomavirus Sexual Health Sept 2010, Vol 7, Issue 3
Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia’s role.
Garland SM,
Brotherton JML,
Fairley CK,
Gertig DM,
Saville M.
Sexual Health, 2010, 7 (3): 227-229.
Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy
Brotherton JML,
Kaldor JM,
Garland SM..
Sexual Health, 2010, 7(3),310-19.
Estimating the incidence of, and treatment patterns for, juvenile onset recurrent respiratory papillomatosis in Australia pre vaccination: a pilot study.
Novakovic D,
Cope D,
Cheng ALT,
Brotherton JML..
Sexual Health, 2010, 7 (3), 19 Aug 2010, 253-61.
Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.
Brotherton JML,
Fairley CK,
Garland SM,
Gertig DM,
Saville M.
Sexual Health, 2010, 7 (3): 397-398.
National survey of the general practitioner’s experience of delivering the National Human Papillomavirus Vaccination Program.
Brotherton JML,
Leask J,
Jackson C,
McCaffery K,
Trevena LJ..
Sexual Health, 2010, 7:291-298.
“Is cancer contagious?”: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV Vaccination.
Cooper Robbins SC,
Bernard D,
McCaffery K,
Brotherton J,
Skinner SR..
Vaccine, 2010, 28, issue 19, 26 April 2010, 3398-3408
Australia needs a national centre for disease control [letter].
Brotherton JML,
Kaldor JM,
Saville M..
Med J Aust, 2010, 193 (10): 623-624.
Abnormal Pap tests after the HPV vaccine.
Heley S,
Brotherton J..
Aust Family Physician, 2009, 38 (12): 977-9, Dec 2009.
Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.
Agorastos T,
Chatzigeorgiou K,
Brotherton JML,
Garland SM..
Vaccine, 2009, 27 (52), 9 Dec 09, 7270-7281.
The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JML,
Heywood A,
Heley S.
Sexual Health, 2009, 6 (3):178-184
Estimating coverage of the National HPV Vaccination Program: where are we at? [letter] .
Brotherton JML,
Mullins R..
Med J Aust, 2009, 191(3):188
Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk Factors, Epidemiology and Prevention.
Garland Suzanne,
Brotherton Julia,
Skinner Richard,
Pitts Marian,
Saville Marion,
Mola Glen,
Jones Ronald.
Vaccine, 2008, 26; Suppl 12, M80-M88, 9 Aug 2008.
Outstanding Problems – Glandular Lesions.
Saville Marion,
Bloomfield Penny.
Cancer Forum, 2008, July 2008; 32 (2).
Temporal Associations with Declining Trichomonas vaginalis Diagnosis Rates Among Women in the State of Victoria Australia, 1947 to 2005.
Marrone John,
Fairley Christopher,
Saville Marion.
Sexually Transmitted Diseases, Jun 2008, 35 (6), 572-576